Sinopharm (Beijing): BBIBP-CorV
Vaccine Type: Inactivated
Vaccine Trial & Approval Tracker
This vaccine is approved.
Phase 1: 1 Trial
-
ChiCTR2000032459
China
Phase 2: 2 Trials
-
NCT04962906
Argentina -
ChiCTR2000032459
China
Phase 3: 5 Trials
-
ChiCTR2000034780
United Arab Emirates -
NCT04612972
Peru -
NCT04510207
Bahrain, Egypt, Jordan, United Arab Emirates -
NCT04917523
United Arab Emirates -
NCT04560881, BIBP2020003AR
Argentina
Approvals
59 Countries
- Angola
- Argentina
- Bahrain
- Bangladesh
- Belarus
- Belize
- Bolivia (Plurinational State of)
- Brazil
- Brunei Darussalam
- Cambodia
- Cameroon
- Chad
- China
- Comoros
- Egypt
- Equatorial Guinea
- Gabon
- Gambia
- Georgia
- Guyana
- Hungary
- Indonesia
- Iran (Islamic Republic of)
- Iraq
- Jordan
- Kyrgyzstan
- Lao People's Democratic Republic
- Lebanon
- Malaysia
- Maldives
- Mauritania
- Mauritius
- Mongolia
- Montenegro
- Morocco
- Mozambique
- Namibia
- Nepal
- Niger
- North Macedonia
- Pakistan
- Paraguay
- Peru
- Philippines
- Republic of the Congo
- Senegal
- Serbia
- Seychelles
- Sierra Leone
- Solomon Islands
- Somalia
- Sri Lanka
- Thailand
- Trinidad and Tobago
- Tunisia
- United Arab Emirates
- Venezuela (Bolivarian Republic of)
- Viet Nam
- Zimbabwe
Registered Trials
-
ChiCTR2000034780
Phase 3United Arab Emirates
Total Enrollment: 45,000
Official Trial Registration:
-
NCT04612972
Phase 3Peru
Total Enrollment: 6,000
Official Trial Registration:
-
NCT04510207
Phase 3Bahrain, Egypt, Jordan, United Arab Emirates
Total Enrollment: 45,000
Official Trial Registration:
-
NCT04917523
Phase 3United Arab Emirates
Total Enrollment: 1,800
Official Trial Registration:
-
NCT04560881, BIBP2020003AR
Phase 3Argentina
Total Enrollment: 3,000
Official Trial Registration:
-
NCT04962906
Phase 2Argentina
Total Enrollment: 150
Official Trial Registration:
-
ChiCTR2000032459
Phase 1/2China
Total Enrollment: 640
Official Trial Registration: